Cell and Gene Commercialization

31. Important Ethical Questions Concerning CGTs 11/3/2023

    This is a summary of Alliance For Regenerative Medicine's panel discussion, "The Importance Of Ethics In Gene And Cell Therapy," from this year's Meeting On The Mesa.

32. Inside 2023 Meeting On The Mesa With ARM's COO, Rita Johnson-Greene 10/26/2023

    Hear from speakers on the Cell & Gene: The Podcast about Meeting on the Mesa 2023, the events new location for 2024, major topics and trends at this year's event, and ARM's GROW internship program.

33. 5 Takeaways From Meeting On The Mesa 2023 10/25/2023

    This year's conference delivered outstanding networking, presentations, and panel discussions with industry leaders. Here are 5 of my favorite quotes from this year's participants.

34. Crafting An Effective Commercialization Strategy For CGTs 10/25/2023

    Patient access and manufacturing efficiency persist as barriers to widespread adoption of CGTs. An effective commercialization strategy is crucial to expand access to these life-changing therapies.

35. ARM’s 2023 Meeting On The Mesa: Data, Ethics, And More 10/19/2023

    ARM's 2023 Meeting on the Mesa was chock full of informative sessions, impactful conversations, partnering opportunities, and peer networking. Here's a brief recap.

36. Expert Solutions From Concept To Commercialization 10/19/2023

    Get the assistance your teams need to translate exceptional concepts and groundbreaking science into transformative treatments that bring hope to those facing unmet medical needs.

37. Planning for Success: Supply Resiliency Strategies for Bench to Production 10/18/2023

    Build scalable material sourcing strategies for R&D and early phases through to commercialization and learn how to accelerate the development process and ensure the scalability of your biologics.

38. Leveraging Automation To Drive Down Costs For Cell Therapy Production 10/18/2023

    Achieving improvements to a cell therapy workflow through automation can greatly improve the consistency of production, bolster a product’s safety and quality, reduce rework, and improve costs.

39. Transitioning From Using RUO To cGMP Chemicals For Clinical Trials 10/17/2023

    Learn about the common challenges and risks associated with accelerating your molecule's timeline from lab to clinic, along with important supply chain considerations for emerging biopharma companies.

40. Supporting Bench To Production Applications For Multiple Industries 10/17/2023

    Grow and scale up your manufacturing with the right support, and choose from 92,000+ chemicals provided through an extensive global network of 3,500+ manufacturers.